home / stock / ptct / ptct news


PTCT News and Press, PTC Therapeutics Inc. From 02/11/24

Stock Information

Company Name: PTC Therapeutics Inc.
Stock Symbol: PTCT
Market: NASDAQ
Website: ptcbio.com

Menu

PTCT PTCT Quote PTCT Short PTCT News PTCT Articles PTCT Message Board
Get PTCT Alerts

News, Short Squeeze, Breakout and More Instantly...

PTCT - PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

2024-02-11 18:00:00 ET Summary PTC Therapeutics has a diverse portfolio and pipeline of drugs, including a broader DMD treatment. The company has not fully expanded its revenue-generating products geographically and is in the process of making the necessary submissions to do so. ...

PTCT - Russell 2000 Q4 2023 Earnings Preview: The Bar Is Set Lower Once Again

2024-01-31 00:21:00 ET Summary Q4 marks the end of a difficult year for Russell 2000 earnings. Energy is no longer the 'top dog' from an earnings growth contribution perspective. Financials has the largest earnings weight for the second consecutive quarter. By Taji...

PTCT - PTC Therapeutics down 10% as EMA issues Translarna negative opinion

2024-01-25 17:30:32 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript PTC Therapeutics says total unaudited FY23 net revenue was about $946M PTC Therapeutics issues EU, US regulatory updates on Translarna Seeking Alpha...

PTCT - DWAC, OCUL and APPF are among after hour movers

2024-01-25 16:59:42 ET Gainers: Ocular Therapeutix,  ( OCUL ) +5% . AppFolio ( APPF ) +4% . Sagimet Biosciences  ( SGMT ) +3% . Xcel Energy  ( XEL ) +3% . Digital World Acquisition  ( DWAC ) +2% . Losers...

PTCT - CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna(TM) (ataluren) Following Re-examination Procedure

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anno...

PTCT - PTC Therapeutics says total unaudited FY23 net revenue was about $946M

2024-01-08 11:40:25 ET More on PTC Therapeutics PTC Therapeutics issues EU, US regulatory updates on Translarna PTC Therapeutics stock slides after Citi downgrades to Sell Seeking Alpha’s Quant Rating on PTC Therapeutics Historical earnings data for PT...

PTCT - PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire &#x...

PTCT - PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 3, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42 n...

PTCT - (PTCT) Investment Report

2023-12-23 05:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

PTCT - PTC Therapeutics issues EU, US regulatory updates on Translarna

2023-12-05 17:53:48 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript PTC Therapeutics stock slides after Citi downgrades to Sell PTC Therapeutics GAAP EPS of -$1.76 misses by $0.70, revenue of $196.6M misses by $15.07M ...

Previous 10 Next 10